Brolucizumab-dbll (Beovu) demonstrates non inferiority to aflibercept in phase 3 KERSTREL and KITE phase 3 trials in diabetic macular oedema

Brolucizumab-dbll was linked to a mean gain from baseline in best corrected visual activity of 9.2 and 10.6 letters in the KERSTREL and KITE trials, respectively ( vs. 10.5 and 9.4 for aflibercept) and was well tolerated.

Source:

Biospace Inc.